Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are currently approved for the treatment of metastatic renal cell carcinoma (mRCC). The cardiotoxic effects of sorafenib and sunitinib may cause hypertension, left ventricular ejection fraction (LVEF) dysfunction and/or congestive heart failure (CHF), an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantaleo, Maria Abbondanza, Mandrioli, Anna, Saponara, Maristella, Nannini, Margherita, Erente, Giovanna, Lolli, Cristian, Biasco, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407789/
https://www.ncbi.nlm.nih.gov/pubmed/22687270
http://dx.doi.org/10.1186/1471-2407-12-231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407789/
https://www.ncbi.nlm.nih.gov/pubmed/22687270
http://dx.doi.org/10.1186/1471-2407-12-231

Ejemplares similares